CSL Ltd. has agreed to acquire Novartis’ global flu vaccine business for $275 million. The business brings a diversified product portfolio with pre-pandemic and pandemic franchises. It will be combined with CSL’s subsidiary, bioCSL, expanding existing flu vaccine operations and creating the second largest player in the $4 billion global flu vaccine industry, with manufacturing plants in the U.S., UK, Germany and Australia.   Novartis’ flu vaccine business had sales of $527 million in...